Clinical trial
INHALE-3: A 17-Week Randomized Trial and a 13-Week Extension, Evaluating the Efficacy and Safety of Inhaled Insulin (Afrezza) Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes
NCT05904743 is registered in ClinicalTrials.gov with Mannkind Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- INHALE-3: A 17-Week Randomized Trial and a 13-Week Extension, Evaluating the Efficacy and Safety of Inhaled Insulin (Afrezza) Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes
- Lead sponsor
- Mannkind Corporation
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- July 7, 2023
- Completion date
- June 24, 2024
- Enrollment
- 141 (actual)
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.